公开(公告)号：WO2014153620A1

公开(公告)日：2014-10-02

申请号：PCT/AU2014/000342

申请日：2014-03-28

Applicant: THE UNIVERSITY OF WESTERN AUSTRALIA ,  JIANG, Fang-XU

Inventor： JIANG, Fang-XU

IPC: C12N5/095 ,  A61K35/39 ,  A61P5/48

CPC classification number: A61K35/39 ,  C12N5/0676 ,  C12N2500/38 ,  C12N2501/40 ,  C12N2506/22

Abstract: The present invention relates to methods for generating mature insulin-producing β-like cells comprising the steps: (a) isolating, purifying and/or enriching β-cell progenitor cells from a population of cells; (b) differentiation of the β-cell progenitor cells into immature insulin-producing β-like cells; and (c) maturation of the immature insulin-producing β-like cells into mature insulin-producing β-like cells, comprising exposing the immature insulin-producing β-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing β-like cells for use in treating diabetes.

Abstract translation: 本发明涉及产生成熟胰岛素生产和类似细胞的方法，其包括以下步骤：（a）从细胞群中分离，纯化和/或富集和培养细胞祖细胞; （b）将细胞祖细胞分化成未成熟的产生胰岛素的细胞; 和（c）将未成熟的产生胰岛素的类细胞成熟为成熟的胰岛素生产和类似细胞，包括将未成熟的产生胰岛素的细胞暴露于骨化三醇或其类似物。 更具体地，本发明涉及产生用于治疗糖尿病的成熟胰岛素生产和类似细胞的方法。

公开(公告)号：WO2014153294A1

公开(公告)日：2014-09-25

申请号：PCT/US2014/030729

申请日：2014-03-17

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： MARTIN, Martin, G. ,  DUNN, James, C.Y. ,  STELZNER, Matthias

IPC: C12N5/02 ,  C12N5/074

CPC classification number: C12N5/068 ,  A61K35/38 ,  A61K48/00 ,  C12N5/0679 ,  C12N2501/11 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2502/23

Abstract: A cell culture media composition for support growth of human SI stem cells and epithelium without a feeder layer is presented. The media may also include growth factors including ENR and Y-27632 that support the survival of stem cell spheroid structures. The cell culture media compositions permit rapid growth of human small intestinal (SI) epithelium and stem cells, which leads to specific spheroid cell and enteroid morphology when grown in 3-D culture system.

Abstract translation: 提出了用于支持人SI干细胞和没有饲养层的上皮的生长的细胞培养基组合物。 培养基还可能包括生长因子，包括支持干细胞球体结构存活的ENR和Y-27632。 细胞培养基组合物允许人类小肠（SI）上皮细胞和干细胞的快速生长，当在3-D培养系统中生长时，其导致特定的球形细胞和肠形成形态。

公开(公告)号：WO2014097192A2

公开(公告)日：2014-06-26

申请号：PCT/IB2013/061110

申请日：2013-12-18

Applicant: CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA MOLECULAR - UNIVERSIDADE DE COIMBRA

Inventor： ESMERALDO DE CAMPOS VAZÃO, Helena Sofia ,  DA SILVA FERREIRA, Lino ,  MACHADO FERNANDES, Hugo Agostinho

IPC: C12N5/00

CPC classification number: C12N5/069 ,  C12N2501/165 ,  C12N2501/40 ,  C12N2501/42 ,  C12N2501/50 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2521/00

Abstract: The present disclosure relates to a differentiated cell population of endothelial cells derived from human pluripotent stem cells. The present invention also relates to a composition, a system and a kit comprising those cells and uses thereof. The present disclosure also described the combination of arterial ECs derived from human pluripotent stem cells with a microfluidic system to create a vascular kit for high-throughput drug screening and/or toxicology analysis. This technology may find particular use for the identification of drugs that may have a fetal cytotoxic effect.

Abstract translation: 本公开涉及源自人多能干细胞的内皮细胞的分化细胞群。 本发明还涉及包含这些细胞的组合物，系统和试剂盒及其用途。 本公开还描述了源自人多能干细胞的动脉EC与微流体系统的组合，以产生用于高通量药物筛选和/或毒理学分析的血管试剂盒。 该技术可能特别用于鉴定可能具有胎儿细胞毒性作用的药物。

公开(公告)号：WO2014018691A1

公开(公告)日：2014-01-30

申请号：PCT/US2013/051913

申请日：2013-07-24

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： SNOECK, Hans-Willem ,  HUANG, Sarah Xuelian ,  CHEN, Ya-Wen

IPC: C12Q1/02 ,  C12N5/071

CPC classification number: C12N5/0689 ,  C12N5/0688 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/23 ,  G01N33/5044 ,  G01N33/6887 ,  G01N2333/78 ,  G01N2500/04 ,  G01N2500/10

Abstract: Embodiments of the present invention are directed to various methods for generating airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres, and to populations of cells made using the methods. The airway and lung progenitors and epithelial cells can be used as a model to study diseases that primarily affect airway epithelial cells, and to study human lung development. Methods are also provided for drug screening. Anterior foregut spheres can be used as a model for lung fibrosis.

Abstract translation: 本发明的实施方案涉及用于产生气道和肺祖细胞，上皮细胞和三维前前肠球以及使用该方法制备的细胞群的各种方法。 气道和肺祖细胞和上皮细胞可用作模型，以研究主要影响气道上皮细胞的疾病，并研究人肺发育。 还提供了用于药物筛选的方法。 前排前球可用作肺纤维化模型。

公开(公告)号：WO2014013255A1

公开(公告)日：2014-01-23

申请号：PCT/GB2013/051917

申请日：2013-07-18

Applicant: THE COMMON SERVICES AGENCY ,  UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

Inventor： MOUNTFORD, Joanne ,  OLIVER, Emmanuel

IPC: C12N5/078

CPC classification number: C12N5/0641 ,  C12N2501/01 ,  C12N2501/113 ,  C12N2501/125 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/39 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45

Abstract: This invention provides method and media suitable for inducing and supporting the differentiation of stem cells into erythroid cells.

Abstract translation: 本发明提供了适于诱导和支持干细胞分化成红细胞的方法和培养基。

公开(公告)号：WO2013158890A1

公开(公告)日：2013-10-24

申请号：PCT/US2013/037186

申请日：2013-04-18

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： FLORES, Elsa, R. ,  CHAKRAVARTI, Deepavali

IPC: C12N5/0735 ,  C12N5/10 ,  C12N15/63 ,  C12N15/113

CPC classification number: A61K35/12 ,  C12N5/0696 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2501/40 ,  C12N2501/998 ,  C12N2506/094 ,  C12N2510/00

Abstract: The present invention generally concerns particular methods and compositions for generation of induced pluripotent stem cells. In particular aspects, induced pluripotent stem cells are generated from adult somatic cells following downregulation of a particular gene of interest. In some embodiments, induced pluripotent stem cells are generated from keratinocytes upon downregulation of ΔΝρ63 or DGCR8.

Abstract translation: 本发明一般涉及用于产生诱导多能干细胞的具体方法和组合物。 在特定方面，诱导的多能干细胞是在特定的感兴趣基因下调之后从成体体细胞产生的。 在一些实施方案中，诱导的多能干细胞在DeltaNurho63或DGCR8下调时由角质细胞产生。

公开(公告)号：WO2013086570A1

公开(公告)日：2013-06-20

申请号：PCT/AU2012/001525

申请日：2012-12-13

Applicant: FLINDERS UNIVERSITY OF SOUTH AUSTRALIA

Inventor： ZHOU, Xin-Fu ,  HAN, Yanchuang

IPC: C12N5/074

CPC classification number: C12N5/0623 ,  C12N5/0619 ,  C12N5/0622 ,  C12N2500/38 ,  C12N2501/065 ,  C12N2501/40 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/1307 ,  G01N33/5073

Abstract: The present invention provides a method of producing a multipotent stem cell, said method comprising culturing at least one fibroblast cell in the presence of an effective amount of at least one small molecule reprogramming factor(s) that induces the cell to de-differentiate into a multipotent stem cell, wherein the method excludes the use of reprogramming factor(s) that are not small molecules. The small molecule reprogramming factor(s) may include a G9a HMTase inhibitor(s) and/or a MEK inhibitor(s) optionally in combination with other small molecule reprogramming factor(s). The invention also includes methods of differentiating the multipotent stem cells, cells produced by the methods, assays using the cells and kits for use in the methods.

Abstract translation: 本发明提供了一种产生多能干细胞的方法，所述方法包括在存在有效量的至少一种小分子重编程因子的情况下培养至少一种成纤维细胞，所述小分子重编程因子诱导细胞脱分化为 多能干细胞，其中该方法不包括使用不是小分子的重编程因子。 小分子重编程因子可以包括任选与其它小分子重编程因子组合的G9a HMTase抑制剂和/或MEK抑制剂。 本发明还包括区分多能干细胞，通过该方法产生的细胞，使用细胞的测定法和用于该方法的试剂盒的方法。

公开(公告)号：WO2013086236A2

公开(公告)日：2013-06-13

申请号：PCT/US2012/068305

申请日：2012-12-06

Applicant: ADVANCED CELL TECHNOLOGY, INC.

Inventor： MCCABE, Kathryn, L. ,  LU, Shi-Jiang ,  LANZA, Robert

IPC: C12N5/071 ,  A61L27/38 ,  A61K35/12

CPC classification number: C12N5/0621 ,  A61K9/0048 ,  A61K35/30 ,  A61K45/06 ,  A61L27/3808 ,  A61L27/3839 ,  A61L27/3895 ,  A61L2430/16 ,  C12N5/0623 ,  C12N2500/60 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/08 ,  C12N2506/45 ,  C12N2533/50

Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more "youthful" gene expression relative to cells obtained from donated tissue.

Abstract translation: 本公开一般涉及用于治疗视觉障碍（包括角膜疾病）的基于细胞的疗法。 方法用于角膜细胞与干细胞的定向分化。 还提供了角膜内皮细胞的组合物及其用途。 示例性组合物相对于从捐赠组织获得的细胞，显示改善的细胞密度和/或更“年轻”的基因表达。

公开(公告)号：WO2013002880A1

公开(公告)日：2013-01-03

申请号：PCT/US2012/033672

申请日：2012-04-13

Applicant: THE GENERAL HOSPITAL CORPORATION ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  TILLY, Jonathan, Lee ,  SINCLAIR, David, A.

Inventor： TILLY, Jonathan, Lee ,  SINCLAIR, David, A.

IPC: C12N5/00 ,  C12N5/075

CPC classification number: C12N15/873 ,  A61K31/05 ,  A61K31/137 ,  A61K31/277 ,  A61K31/352 ,  A61K31/4745 ,  A61K31/498 ,  A61K35/14 ,  A61K35/28 ,  A61K35/51 ,  A61K35/54 ,  C07D213/50 ,  C07D233/60 ,  C07D233/88 ,  C07D277/36 ,  C07D277/587 ,  C07D277/64 ,  C07D495/04 ,  C12N5/0609 ,  C12N5/0682 ,  C12N2501/40 ,  C12N2517/10

Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility- enhancing procedures, are described.

Abstract translation: 描述了包含用于恢复老化卵母细胞质量，增强卵母细胞或改善其生殖力增强程序的衍生物（例如细胞质或分离的线粒体）的生物能量剂的组合物和方法。

公开(公告)号：WO2012064090A9

公开(公告)日：2012-08-23

申请号：PCT/KR2011008473

申请日：2011-11-08

Applicant: KWANGJU INST SCI & TECH ,  WILLIAMS DARREN R ,  JUNG DA-WOON

Inventor： WILLIAMS DARREN R ,  JUNG DA-WOON

IPC: C12N5/077 ,  A61K35/34 ,  A61P21/00 ,  C12N5/02

CPC classification number: C12N5/0696 ,  C12N5/0668 ,  C12N2501/06 ,  C12N2501/40 ,  C12N2506/1323

Abstract: The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating the differentiated cells with a dedifferentiation agent after inducing the down-regulation of p21 expression of the differentiated cells. The multipotent cells of the invention enable not only dedifferentiation into a musculogenesis cell population but also the transdifferentiation into an adipogenesis cell population or an osteogenesis cell population. Therefore, the chemical-based approach method of the invention is important in the development of strategies for inducing limb regeneration in mammals. In addition, the invention discloses a new approach method for the development of induced pluripotent stem cells (iPSCs) from completely differentiated refractory tissues.